Roivant Sciences (ROIV) vs Sanofi (SNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Roivant Sciences (ROIV) has outperformed Sanofi (SNY) over the past year, gaining 113.4% versus a loss of 17.6%. Over five years, ROIV leads with a +468.3% price change compared with -17.6% for SNY. Sanofi is the larger company by market cap ($96.40 billion vs $24.71 billion), about 3.9 times the size.
Sanofi pays a dividend yielding 10.24%, while Roivant Sciences does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ROIV | SNY |
|---|---|---|
| Share price | $34.21 | $40.23 |
| Market cap | $24.71B | $96.40B |
| 1-day change | -1.55% | +0.07% |
| YTD return | +57.65% | -16.98% |
| 1-year return | +113.41% | -17.56% |
| 5-year return | +468.27% | -17.65% |
| P/E ratio (TTM) | — | 21.17 |
| Forward P/E | — | 7.45 |
| EPS (TTM) | $-0.53 | $1.90 |
| Dividend yield | 0.00% | 10.24% |
| Annual dividend | $0.00 | $4.12 |
| Revenue (latest FY) | $8.26M | — |
| Revenue growth (YoY) | -71.57% | — |
| Net income (latest FY) | $-299.77M | — |
| Operating margin | -6235.69% | — |
| Net margin | -3629.19% | — |
| 52-week high | $42.50 | $52.68 |
| 52-week low | $15.90 | $39.18 |
| Distance from 52-week high | -19.51% | -23.63% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +40.54% | +33.26% |
| Average volume | 7.04M | 2.89M |
| Shares outstanding | 722.32M | 2.40B |
| Employees | 721 | 74,846 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sanofi is about 3.9 times larger than Roivant Sciences by market value ($96.40B vs $24.71B).
- ROIV has outperformed SNY by 131.0 percentage points over the past year.
- Sanofi offers a meaningfully higher dividend yield (10.24% vs 0.00%).
About Roivant Sciences
ROIV stock →Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 721 employees
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
ROIV vs SNY FAQ
Which is bigger, Roivant Sciences or Sanofi?
Sanofi (SNY) is larger, with a market capitalization of $96.40B compared with $24.71B for Roivant Sciences (ROIV).
Which stock has performed better over the past year, ROIV or SNY?
ROIV returned +113.41% over the past 12 months, compared with -17.56% for SNY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Roivant Sciences or Sanofi?
Sanofi pays a dividend yielding 10.24%, while Roivant Sciences does not currently pay a regular dividend.
Are Roivant Sciences and Sanofi in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.